<DOC>
	<DOCNO>NCT00895895</DOCNO>
	<brief_summary>The study evaluate efficacy safety investigational drug call SAM-531 three dosage level . Subjects receive either one 3 dosage level SAM-531 , donepezil placebo first 24 week study ( period I ) . Subjects receive placebo period I assign receive high dose SAM-531 SAM-531 remain 28 week study , subject receive one three SAM-531 dosage level donepezil period I continue study drug ( period II ) .</brief_summary>
	<brief_title>Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease</brief_title>
	<detailed_description>The study stop ( date termination 13April2011 ) due 6 month interim analysis : 3 SAM-531 dosage level declare futile . There safety concern .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Diagnosis probable Alzheimer Disease accord National Institute Neurological Communicative Disorders StrokeAlzheimer 's Diseases Related Disorders Association ( NINCDSADRDA ) criterion . MiniMental State Examination ( MMSE ) score 12 24 screen Rosen Modified Hachinski Ischemic score &lt; equal 4 screening . Relevant neurologic disease Alzheimer Disease may affect cognition ability complete study . Current major depressive disorder current major psychiatric disorder . History clinically evident stroke clinically important carotid vertebrobasilar stenosis plaque . Use prescription nonprescription medication cognitive enhancement ( include memantine , ginkgo biloba , huperzine A , cholinesterase inhibitor ) within 3 month baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>